Results 111 to 120 of about 25,289 (245)
Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights
British Journal of Pharmacology, EarlyView.Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra +5 more
wiley +1 more source
Valsartan, Nebivolol and Blood Pressure
, 2010 BackgroundThe exploration of Blood Pressure (BP) variability and of the influence of different antihypertensive drugs on BP variability may improve understanding of the mechanism involved in BP changes induced by drugs.
Stefania Negrea; “luliu Hatieganu” University of Medicine and Pharmacy Cluj-Napoca, Romania +2 more
core
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and chronic heart failure (CHF). Despite clinical guideline recommendations, SGLT2i uptake in UK primary care remains suboptimal and information on utilisation is limited.
Chelsea Stefanska +6 more
wiley +1 more source
Angiotensin II receptor blocker valsartan enhances glucose-induced insulin secretion [PDF]
, 2006 A number of antihypertensive drugs are known to be diabetogenic. This may contribute to less than expected decrease in the incidence of coronary heart disease with reduction in blood pressure with treatment in hypertensive patients.
Azdan, Zulnizam +3 more
core
, 2004 Hypertension is a rapidly moving clinical field with frequent developments in new pharmacologic agents and management strategies. Perhaps more importantly, there have been substantial improvements in our understanding of how best to use the drugs ...
Farrugia, Emanuel
core
, 2022 INTRODUCTION: Sacubitri l / valsartan is a drug recommended since 2015 for the treatment of heart failure. While the cardiovascular action of this drug is recognized, questions have been raised regarding its neurocognitive action, in particular a risk of
Guion-Firmin, Julia
core
Journal of Sleep Research, Volume 34, Issue 2, April 2025.Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont +5 more
wiley +1 more source
Metagenomic Evaluation of Oral Microbiota in Patients Affected by Oral Lichen Planus: A Pilot Study
Oral Diseases, EarlyView.ABSTRACT Objective To characterize the oral bacterial and fungal microbiota of symptomatic oral lichen planus patients undergoing topical corticosteroid therapy and to explore microbial patterns potentially associated with subsequent oral candidiasis. Methods Twelve patients with clinically and histologically confirmed OLP were enrolled.
A. Dormiente +5 more
wiley +1 more source
Advanced Conduction Disease After Incident Heart Failure in Myotonic Dystrophy Type 1
Pacing and Clinical Electrophysiology, EarlyView.Central Figure. Advanced Conduction Disease After Incident HF in Myotonic Dystrophy Type 1. ABSTRACT Background Myotonic dystrophy type 1 (DM1) is associated with progressive cardiac conduction disease, heart failure (HF) and increased mortality. However, the association of incident HF with conduction disease and survival in DM1 is not well defined ...
Isadora Guarino +3 more
wiley +1 more source
Research Results in PharmacologyIntroduction: Parkinson’s disease is the second most common complex progressive neurodegenerative disease after Alzheimer’s disease. Tremor, stiffness, and bradykinesia are common symptoms, additionally to postural instability as the condition advances ...
Asmaa Abdulwahab Ahmed +3 more
doaj +1 more source